Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in
chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving imatinib mesylate
together with capecitabine may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate
when given together with capecitabine in treating patients with advanced solid tumors.